Analyst Price Targets — EXEL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 14, 2026 9:39 am | Etzer Darout | Barclays | $49.00 | $56.04 | TheFly | Exelixis price target raised to $49 from $45 at Barclays |
| July 13, 2026 11:09 am | — | Wells Fargo | $49.00 | $56.50 | TheFly | Exelixis price target raised to $49 from $40 at Wells Fargo |
| July 7, 2026 11:30 am | — | RBC Capital | $46.00 | $55.53 | TheFly | Exelixis price target raised to $46 from $43 at RBC Capital |
| July 2, 2026 12:47 pm | Ashwani Verma | UBS | $52.00 | $55.46 | TheFly | Exelixis price target raised to $52 from $43 at UBS |
| July 2, 2026 10:42 am | Robert Burns | H.C. Wainwright | $56.00 | $53.96 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Exelixis (EXEL) |
| June 25, 2026 10:13 am | Gregory Renza | Truist Financial | $54.00 | $52.87 | StreetInsider | Truist Securities Assumes Exelixis (EXEL) at Hold |
| April 20, 2026 9:24 am | — | Barclays | $45.00 | $44.89 | TheFly | Exelixis price target raised to $45 from $44 at Barclays |
| February 12, 2026 11:05 am | — | H.C. Wainwright | $54.00 | $42.94 | TheFly | Exelixis price target raised to $54 from $52 at H.C. Wainwright |
| February 11, 2026 12:11 pm | — | Stifel Nicolaus | $44.00 | $42.98 | TheFly | Exelixis price target raised to $44 from $43 at Stifel |
| February 4, 2026 10:46 am | Etzer Darout | Barclays | $44.00 | $42.59 | TheFly | Exelixis price target raised to $44 from $41 at Barclays |
Latest News for EXEL
Allspring Global Investments Holdings LLC grew its holdings in Exelixis, Inc. (NASDAQ: EXEL) by 23.4% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,707,715 shares of the biotechnology company's stock after acquiring an additional 323,895 shares during the period. Allspring Global
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
These three biotechs are posting strong revenue growth. Brand-new launches and label expansions should help them improve their lineups.
Exelixis' zanzalintinib faces a setback, but an FDA review, phase III trials and Cabometyx momentum keep investors focused on its growth path.
Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for EXEL.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.